NO20032091L - Blandinger av N-(metyletylaminokarbonyl)-4-(3- metylfenylamino)-3-pyridylsulfonamid og sykliske oligosakkarider - Google Patents

Blandinger av N-(metyletylaminokarbonyl)-4-(3- metylfenylamino)-3-pyridylsulfonamid og sykliske oligosakkarider

Info

Publication number
NO20032091L
NO20032091L NO20032091A NO20032091A NO20032091L NO 20032091 L NO20032091 L NO 20032091L NO 20032091 A NO20032091 A NO 20032091A NO 20032091 A NO20032091 A NO 20032091A NO 20032091 L NO20032091 L NO 20032091L
Authority
NO
Norway
Prior art keywords
pyridylsulfonamide
methylethylaminocarbonyl
methylphenylamino
mixtures
cyclic oligosaccharides
Prior art date
Application number
NO20032091A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032091D0 (no
Inventor
Miljenko Dumic
Darko Filic
Bozena Klepic
Aleksandar Danilovski
Marijan Tudja
Original Assignee
Pliva Pharm & Chem Works
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Pharm & Chem Works filed Critical Pliva Pharm & Chem Works
Publication of NO20032091D0 publication Critical patent/NO20032091D0/no
Publication of NO20032091L publication Critical patent/NO20032091L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
NO20032091A 2000-11-10 2003-05-09 Blandinger av N-(metyletylaminokarbonyl)-4-(3- metylfenylamino)-3-pyridylsulfonamid og sykliske oligosakkarider NO20032091L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HR20000765A HRP20000765A2 (en) 2000-11-10 2000-11-10 Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release
PCT/HR2001/000004 WO2002038186A1 (en) 2000-11-10 2001-01-31 Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides

Publications (2)

Publication Number Publication Date
NO20032091D0 NO20032091D0 (no) 2003-05-09
NO20032091L true NO20032091L (no) 2003-07-02

Family

ID=10947206

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032091A NO20032091L (no) 2000-11-10 2003-05-09 Blandinger av N-(metyletylaminokarbonyl)-4-(3- metylfenylamino)-3-pyridylsulfonamid og sykliske oligosakkarider

Country Status (26)

Country Link
US (1) US7037928B2 (is)
EP (1) EP1347780B1 (is)
JP (1) JP2004513155A (is)
KR (1) KR20030060929A (is)
CN (1) CN1477977A (is)
AR (1) AR026815A1 (is)
AU (1) AU2001228721A1 (is)
BG (1) BG107896A (is)
BR (1) BR0115281A (is)
CA (1) CA2428179A1 (is)
CZ (1) CZ20031490A3 (is)
DE (1) DE60125828T2 (is)
EA (1) EA005111B1 (is)
EE (1) EE200300197A (is)
GE (1) GEP20043403B (is)
HR (1) HRP20000765A2 (is)
HU (1) HUP0400776A2 (is)
IL (1) IL155818A0 (is)
IS (1) IS6810A (is)
MX (1) MXPA03004111A (is)
NO (1) NO20032091L (is)
PL (1) PL361667A1 (is)
SK (1) SK6722003A3 (is)
WO (1) WO2002038186A1 (is)
YU (1) YU35303A (is)
ZA (1) ZA200303601B (is)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI21703A (en) * 2004-01-14 2005-08-31 Lek Farmacevtska Druzba Dd Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia
ES2293530T3 (es) * 2004-01-22 2008-03-16 Pfizer, Inc. Derivados de sulfonamidas para el tratamiento de enfermedades.
CN100372534C (zh) * 2006-04-20 2008-03-05 南京海辰药业有限公司 托拉塞米冻干制剂及制备方法
NZ580162A (en) 2007-04-13 2012-10-26 Millennium Pharm Inc Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
BR102012009317B1 (pt) * 2012-04-20 2022-05-31 Universidade Federal De Minas Gerais - Ufmg Processo de preparação de compostos de inclusão envolvendo ciclodextrinas e fármacos, usando um sistema de fluxo contínuo
CA3123718A1 (en) 2019-01-04 2020-07-09 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
EP3906020A1 (en) * 2019-01-04 2021-11-10 SQ Innovation AG Pharmaceutical compositions of torsemide and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US576511A (en) * 1897-02-02 Georg steinike and friedrich schmidt
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
WO1997021312A2 (en) * 1995-12-01 1997-06-12 Philips Electronics N.V. A digital cordless telephony system, a radio base station, and a combination of a radio base station and a cordless handset
US6828334B2 (en) * 2002-05-23 2004-12-07 Usv Limited Fenofibrate-cyclodextrin inclusion complexes and their pharmaceutical composition

Also Published As

Publication number Publication date
JP2004513155A (ja) 2004-04-30
EP1347780B1 (en) 2007-01-03
IL155818A0 (en) 2003-12-23
AU2001228721A1 (en) 2002-05-21
PL361667A1 (en) 2004-10-04
EE200300197A (et) 2003-08-15
BG107896A (bg) 2004-01-30
KR20030060929A (ko) 2003-07-16
US20040039204A1 (en) 2004-02-26
CZ20031490A3 (cs) 2003-08-13
EA200300556A1 (ru) 2003-08-28
HUP0400776A2 (hu) 2004-08-30
DE60125828D1 (de) 2007-02-15
EA005111B1 (ru) 2004-10-28
IS6810A (is) 2003-05-08
CA2428179A1 (en) 2002-05-16
ZA200303601B (en) 2004-07-19
GEP20043403B (en) 2004-06-10
WO2002038186A1 (en) 2002-05-16
DE60125828T2 (de) 2007-08-16
CN1477977A (zh) 2004-02-25
SK6722003A3 (en) 2003-10-07
MXPA03004111A (es) 2004-05-05
NO20032091D0 (no) 2003-05-09
EP1347780A1 (en) 2003-10-01
HRP20000765A2 (en) 2002-06-30
AR026815A1 (es) 2003-02-26
YU35303A (sh) 2006-03-03
BR0115281A (pt) 2003-07-29
US7037928B2 (en) 2006-05-02

Similar Documents

Publication Publication Date Title
NO20032733L (no) Difenylazetidinonderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene og deres anvendelse
NO20042161L (no) Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1
NO20093060L (no) Spirosykliske sykloheksanderivater
NO20030381D0 (no) Bicyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder slikeforbindelser
NO20025821L (no) 2-aminokarbonyl-9H-purinderivater
NO20054006D0 (no) Cykliske ureaderivater, fremstillingsfremgangsmate derav og farmasoytisk anvendelse av samme som kinaseinhibitorer
DK1294682T3 (da) Acylphenylurinstofderivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel
NO20054905L (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
NO20002486D0 (no) Sykliske aminderivater og deres anvendelse som legemidler
RS50814B (sr) Tartaratne soli 5,8,14-triazatetraciklo(10.3.1.02,11.04,9)- heksadeka-2(11),3,5,7,9-pentaena
EE05475B1 (et) Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
DK1417206T3 (da) Hidtil ukendte 2H-pyridazin-3-on-derivater, farmaceutiske præparater indeholdende det samme, og en fremgangsmåde til fremstilling af den aktive bestanddel
NO20021689L (no) 5-leddede heterocykliske derivater, fremstilling derav og anvendelse som medikamenter
NO20024742D0 (no) Heterocykliske forbindelser, deres fremstilling og anvendelse
NO20033732L (no) N-substituerte ikke-aryl-heterosykliske NMDA/NR2B-antagonister, og farmasoytiske preparater som omfatter slike forbindelser.
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
NO20045486L (no) Nye forbindelser og deres anvendelse
PT1401501E (pt) Composicoes farmaceuticas orais com libertacao modificada do ingrediente activo
DK1095025T3 (da) Benzimidazoler, deres fremstilling og deres anvendelse som lægemidler
DE60209929D1 (de) Succinate des 5,8,14-triazatetracycloä10.3.1.0 2,11 .0 4,9 ü-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
DK1517890T3 (da) Kationisk substituerede diphenylazetidinoner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
NO20032091L (no) Blandinger av N-(metyletylaminokarbonyl)-4-(3- metylfenylamino)-3-pyridylsulfonamid og sykliske oligosakkarider
NO20073071L (no) Benzotiazolformuleringer og anvendelse av disse
DE60121587D1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application